News coverage about Chemed Corp. (NYSE:CHE) has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemed Corp. earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.3129011173462 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Chemed Corp. (CHE) traded down 0.16% on Friday, reaching $191.88. The company had a trading volume of 103,785 shares. The stock has a market cap of $3.07 billion, a PE ratio of 47.60 and a beta of 1.14. Chemed Corp. has a 12 month low of $130.05 and a 12 month high of $216.01. The stock has a 50-day moving average price of $201.50 and a 200-day moving average price of $191.93.

Chemed Corp. (NYSE:CHE) last released its earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.89 by $0.26. The company had revenue of $415.06 million during the quarter, compared to analyst estimates of $407.56 million. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. Chemed Corp.’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.80 earnings per share. Analysts predict that Chemed Corp. will post $8.20 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Monday, August 14th will be issued a $0.28 dividend. The ex-dividend date is Thursday, August 10th. This is a positive change from Chemed Corp.’s previous quarterly dividend of $0.26. This represents a $1.12 annualized dividend and a dividend yield of 0.58%. Chemed Corp.’s dividend payout ratio is currently 28.07%.

Several research analysts recently commented on CHE shares. Zacks Investment Research raised Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price target for the company in a research report on Friday, July 28th. BidaskClub cut Chemed Corp. from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 22nd. TheStreet cut Chemed Corp. from a “b+” rating to a “c+” rating in a research report on Tuesday, July 25th. Royal Bank Of Canada reissued a “hold” rating and set a $208.00 price target on shares of Chemed Corp. in a research report on Wednesday, July 5th. Finally, Oppenheimer Holdings, Inc. increased their price target on Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a research report on Thursday, July 27th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Chemed Corp. presently has a consensus rating of “Hold” and a consensus price target of $218.33.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/12/chemed-corp-che-receiving-somewhat-positive-press-coverage-analysis-shows.html.

In other Chemed Corp. news, Director George J. Walsh III bought 1,000 shares of Chemed Corp. stock in a transaction dated Monday, June 26th. The stock was bought at an average cost of $204.56 per share, with a total value of $204,560.00. Following the completion of the acquisition, the director now directly owns 7,908 shares in the company, valued at approximately $1,617,660.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin J. Mcnamara sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the transaction, the insider now directly owns 173,801 shares of the company’s stock, valued at $34,961,809.16. The disclosure for this sale can be found here. Corporate insiders own 5.32% of the company’s stock.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Insider Buying and Selling by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.